Home/Pipeline/TSC-102-A03

TSC-102-A03

Hematologic Malignancies

PreclinicalIND Cleared by FDA

Key Facts

Indication

Hematologic Malignancies

Phase

Preclinical

Status

IND Cleared by FDA

Company

TScan Therapeutics

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotech company focused on developing transformative TCR-T therapies for oncology, with a secondary research arm in autoimmunity. Founded in 2018, its core asset is a proprietary, high-throughput platform that discovers novel tumor antigens and therapeutic TCRs. Key achievements include an active Phase 1 trial for its lead candidate TSC-101 in post-transplant AML/MDS and FDA clearance for two additional heme candidates. The strategy leverages this platform to build a broad pipeline while advancing next-generation in vivo engineering approaches.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Hematologic Malignancies Drugs

Drug	Company	Phase	Status
CER-T Cell Platform	CERo Therapeutics	Pre-clinical	Research & Development
Not Specified (Hematologic Malignancies)	AbelZeta Pharma	Clinical	Active
PredicineHEME™	Predicine	Commercial	Active
Orca-T	Bristol Myers Squibb	Phase 3	Active
NK‑Thera	Vectorite Biomedical	Phase 1/2	Active
Trichostatin A (TSA)	Vanda Pharmaceuticals	Development	Active
DARIC-NK Program	Coeptis Therapeutics	Preclinical	Lead Optimization
TSC-102-A01	TScan Therapeutics	Preclinical	IND Cleared by FDA
LBL-007	LakeShore Biopharma	Phase 1/2	Active